Obviously, the data revealed a discrepancy between the NKG2DL highly expressed tumor cells, GL261 cells and the NKG2DL lowly expressed tumor cells, EMT-6 cells or the B16 cells, in their tumor genetic capacity in allogeneic mice, especially at the early stage after the tumor cell inoculation, implying that high expression of NKG2DL on tumor cells may determine the early tumor rejection in the allogeneic mice and NKG2D+ cells may be involved in the process rejection. This evidence concerns the gene KLRK1 and neoplasm.